Cenix BioScience Signs Research Agreement with Regulus Therapeutics for miRNA-Targeted Drug Discovery
News Jul 22, 2008
Cenix will apply its expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells.
The company will thereby screen libraries of synthetic miRNA modulators designed and produced by Regulus, using multi-parametric assays to identify novel lead molecules offering highest therapeutic potential in the area of immunology and inflammation.
“Following the long-standing relationship and mutual respect shared with several key members of the starting team at Regulus, we at Cenix are very much looking forward to working together to drive this ground-breaking discovery program forward” said Dr. Christophe Echeverri, CEO/CSO of Cenix.
“Regulus is committed to discovering and developing novel microRNA-targeted therapeutics and adding to a large and growing body of knowledge on how individual microRNAs function within the cell,” said Peter S. Linsley, Ph.D. CSO of Regulus. “We look forward to working collaboratively with Cenix to identify interesting microRNA-targeted drug candidates.”
No further terms of the agreement were released.
Habitat loss, habitat fragmentation and the loss of genetic diversity are the main factors driving the extinction of many wild species, and the few eastern massasauga rattlesnakes remaining in Illinois have certainly suffered two of the three. A long-term study of these snakes reveals, however, that – despite their alarming decline in numbers – they have retained a surprising amount of genetic diversity.READ MORE